I-Remicade vs Humira: Umehluko Omkhulu nokufana

Izidakamizwa Vs. Umngani

I-Remicade (infliximab) ne-Humira (adalimumab) yimithi emibili engaphatha izimo zokuvuvukala ezifana ne-rheumatoid arthritis, isifo sikaCrohn, ne-ulcerative colitis. Yomibili le mithi ihlukaniswa njengama-antibody monoclonal asebenza ngokuvimba izimpendulo ezithile zomzimba. Ngokuvimba izinqubo zokuvuvukala, iRemicade neHumira zinganikeza ukukhululeka okubalulekile kwezimo ezithile. Ukufana nokwehluka kwazo kuzobuyekezwa lapha.

I-Remicade

I-Remicade igama lomkhiqizo le-infliximab. Kuvunyelwe ukwelapha isifo sikaCrohn kubantu abadala kanye nasezinganeni. Kuyamukelwa futhi ukwelapha izimo zokuvuvukala ezifana nesifo samathambo, kodwa kuphela ngokuhlanganiswa nomunye umuthi obizwa ngokuthi yi-methotrexate.

I-Remicade inikezwa njengokufakwa ngaphakathi emthanjeni nguchwepheshe wezokunakekelwa kwempilo. Lokhu kusho ukuthi kuzofanele wenze ukuvakashelwa udokotela ukumnika ngakunye.

I-Remicade idonswa ngezikhathi ezahlukahlukene lapho iqala khona. Isibonelo, ngemuva komthamo wokuqala, unikezwa ngemuva kwamasonto amabili bese ngemuva kwamasonto ayisithupha. Ngemuva kwalokho, unikezwa njalo ezinyangeni lapho welapha isifo seCrohn kubantu abadala.

I-Remicade ayinconywa ngamanani athile kubantu abanesifo senhliziyo esibi.

Humira

I-Humira yigama lomkhiqizo le-adalimumab. Kuvunyelwe ukwelapha isifo sikaCrohn phakathi kwezinye izimo zokuvuvukala. Ingasetshenziswa yodwa noma nge-methotrexate ukwelapha isifo samathambo kubantu abadala nasezinganeni.

I-Humira inganikezwa njengomjovo ngaphansi kwesikhumba ekhaya. Itholakala njenge-40 mg / 0.4 mL, 40 mg / 0.8 mL, kanye ne-80 mg / 0.8 mL ipeni eligcwalisiwe elisetshenziswa kanye. Amasirinji agcwalisiwe angasetshenziswa futhi.

Lapho welapha isifo sikaCrohn kubantu abadala, umthamo wesondlo unikezwa njalo ngesonto.

I-Remicade vs Humira Side by Ukuqhathanisa Okuseceleni

I-Remicade ne-Humira yizidakamizwa ezimbili ezingasetshenziswa ukwelapha izimo ezifanayo. Ngaphandle kokufana kwabo, futhi banokunye umehluko okufanele babuyekezwe. Izici zabo zingaqhathaniswa ngezansi.

I-Remicade	Humira
Okumiselwe i
Isifo sikaCrohn I-ulcerative colitis Isifo samathambo I-psoriatic arthritis I-plaque psoriasis I-Ankylosing spondylitis idra	Isifo sikaCrohn I-ulcerative colitis Isifo samathambo I-juvenile idiopathic arthritis I-psoriatic arthritis I-plaque psoriasis I-Ankylosing spondylitis I-Hidradenitis suppurativa
Ukuhlukaniswa Kwezidakamizwa
Igciwane lomzimba elilodwa Isigaxa se-tumor necrosis factor (TNF)	Igciwane lomzimba elilodwa Isigaxa se-tumor necrosis factor (TNF)
Umkhiqizi
UJanssen Biotech	AbbVie
Imiphumela emibi ejwayelekile
Izifo Ukusabela okuhlobene nokufakwa ngaphakathi (ubuhlungu, ububomvu, ukuvuvukala, njll.) Ukutheleleka okuphezulu okuphefumulayo Ubuhlungu bekhanda Ubuhlungu besisu	Izifo Ukuphendula kwesayithi lokujova (ubuhlungu, ubomvu, ukuvuvukala, njll.) Ubuhlungu bekhanda I-Rash
Ingabe kukhona okujwayelekile?
Akukho okujwayelekile okutholakalayo ukuthengwa	Akukho okujwayelekile okutholakalayo ukuthengwa
Ngabe ihlanganiswe umshwalense?
Iyahluka kuya ngomhlinzeki wakho	Iyahluka kuya ngomhlinzeki wakho
Amafomu Esikali
Ukufakwa ngaphakathi	Umjovo ongaphansi
Inani lentengo emaphakathi
$ 11,502 wokunikezwa kwezigubhu eziyi-10, 100 mg	$ 5,773 wokunikezwa kwamakhithi amabili angaphansi kwesikhumba
Intengo Yesaphulelo Esingabodwa
Inani le-Remicade	Intengo yeHumira
Ukusebenzisana Kwezidakamizwa
Imishanguzo ebukhoma Anakinra Abatacept	Imishanguzo ebukhoma Anakinra Abatacept
Ngingakwazi ukusebenzisa ngenkathi ngihlela ukukhulelwa, ngikhulelwe, noma ngincelisa ibele?
I-Remicade isesigabeni sokukhulelwa B. Akukho monakalo wombungu osungulwe ezifundweni zezilwane. Kodwa-ke, ukulimala kombungu akunqatshelwe. Xhumana nodokotela mayelana nezinyathelo okufanele uzithathe uma uhlela ukukhulelwa noma ukuncelisa ibele.	I-Humira isesigabeni sokukhulelwa B. Akukho monakalo wombungu osungulwe ezifundweni zezilwane. Kodwa-ke, ukulimala kombungu akunqatshelwe. Xhumana nodokotela mayelana nezinyathelo okufanele uzithathe uma uhlela ukukhulelwa noma ukuncelisa ibele.

Isifinyezo

I-Remicade (infliximab) ne-Humira (adalimumab) yimithi efanayo kadokotela engaphatha izimo zokuvuvukala. Zombili lezi zidakamizwa zisebenza njengama-antibody monoclonal futhi, ikakhulukazi njengabavimbeli be-TNF, ukwelapha ukuvuvukala.

I-Humira ingasetshenziselwa ukwelapha i-rheumatoid arthritis kubantu abadala nezingane ezineminyaka engu-2 nangaphezulu. Ngokungafani noHumira, i-Remicade ayiboniswanga ukuthi ilusizo ezinganeni ezineminyaka engu-2 nangaphezulu ezine-arthritis ye-rheumatoid. Noma kunjalo, isengasetshenziswa kubantu abadala abane-arthritis ye-rheumatoid.

I-Remicade inikezwa njengokufakwa ngaphakathi okufakwa ngaphakathi okufanele kufakwe nguchwepheshe wezokunakekelwa kwempilo. I-Humira, ngakolunye uhlangothi, ilawulwa njengepeni lokusebenzisa kanye noma umjovo wesirinji onganikezwa ekhaya.

Kokubili i-Remicade ne-Humira kunemiphumela emibi efanayo nokusebenzisana kwezidakamizwa. Isibonelo, zombili zandisa ubungozi bokutheleleka ngenxa yemiphumela engaba khona kumasosha omzimba. Ngesizathu esifanayo, akufanele zisetshenziswe ngemithi yokugoma ephilayo noma ezinye izidakamizwa ezingathinta amasosha omzimba.

Kubalulekile ukuxoxa ngale mithi nodokotela wakho. Ngenxa yomehluko othile wokuthi zisetshenziswa kanjani, kubalulekile ukubuyekeza isimo sakho jikelele. Imininingwane evezwe lapha yenzelwe ukubuka konke kwezemfundo.